Is the measurement of anti-Müllerian hormone essential?

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 3, 2012, Pages 151-157

  Usta, Taner ^a   Oral, Engin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

anti M llerian hormone; assisted reproduction techniques; obesity; ovarian reserve; PCOS

Indexed keywords

FOLLITROPIN; INHIBIN; MUELLERIAN INHIBITING FACTOR;

ANOVULATION; CLINICAL PRACTICE; FEMALE; FERTILITY; FERTILIZATION IN VITRO; HORMONAL CONTRACEPTION; HORMONE BLOOD LEVEL; HUMAN; INTRAUTERINE INSEMINATION; MENOPAUSE; MENSTRUAL CYCLE; OBESITY; OOCYTE; OOCYTE DONATION; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY OUTCOME; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PUERPERIUM; REVIEW;

AGING; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FERTILIZATION IN VITRO; HUMANS; OBESITY; OVARY; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PREGNANCY;

EID: 84861100822     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283527dcf     Document Type: Review

References (61)

1. Buyuk E, Seifer DB, Younger J, et al. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertil Steril 2011;95:2369-2372. This article examines AMH levels compared with obese and nonobese women with DOR.
2. Broer SL, Mol BW, Dolleman M, et al. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol 2010;22:193-201.
3. Van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter-and intracycle variability of AMH and antral follicle counts. Hum Reprod 2010;25:221-227. This article shows AMH displays less intra-individual fluctuation than the AFC both within and between cycles.
4. Verhagen TE, Hendriks DJ, Bancsi LF, et al. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. Hum Reprod Update 2008;14:95-100.
5. van der Stroom EM, König TE, van Dulmen-den Broeder E, et al. Early menopause in mothers of children with Down syndrome? Fertil Steril 2011;96:985-990. This very recent publication presents women who have had a Down syndrome pregnancy at a younger age show signs of limited ovarian reserve.
6. Pellatt L, Rice S, Dilaver N, et al. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril 2011;96:1246-1251. This very recent publication presents for the first time that AMH inhibits factors promoting follicle progression in human granulosa cells from follicles of the size from which the dominant follicle would be selected.
7. Munsterberg A, Lovell-Badge R. Expression of the mouse anti-Müllerian hormone gene suggests a role in both male and female sexual differentiation. Development 1991;113:613-624.
8. Crisosto N, Codner E, Maliqueo M, et al. Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2739-2743.
9. La Marca A, De Leo V, Giulini S, et al. Antimüllerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J Soc Gynecol Investig 2005;12:545-548.
10. Ledger WL. Clinical utility of measurement of anti-Müllerian hormone in reproductive endocrinology. J Clin Endocrinol Metab 2010;95:5144-5154.
11. Gougeon A. Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. Maturitas 1998;30:137-142.
12. Wunder DM, Bersinger NA, Yared M, et al. Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 2008;89:927-933.
13. Knight PG, Glister C. TGF superfamily members and ovarian follicle development. Reproduction 2006;132:191-206.
14. La Marca A, Broekmans FJ, Volpe A, et al. ESHRE Special Interest Group for Reproductive Endocrinology-AMH Round '. Hum Reprod 2009;24:2264-2275.
15. Hehenkamp WJ, Looman CW, Themmen AP, et al. Antimüllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-4063.
16. Sowers M, McConnell D, Gast K, et al. Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010;94:1482-1486. This article demonstrates that AMH level shows fluctuations during the cycle.
17. Rombauts L, Onwude JL, Chew HW, et al. The predictive value of antral follicle count remains unchanged across the menstrual cycle. Fertil Steril 2011;96:1514-1518. This article presents that AFC can be measured regardless of the phase of the menstrual cycle without apparent effect on its predictive value for poor ovarian response.
18. Riggs R, Kimble T, Oehninger S, et al. Anti-Müllerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation. Fertil Steril 2011;95:410-412. This article showed that AMH was superior to other biomarkers of ovarian reserve in predicting low and high response in young women selected as oocyte donors, but that it was not predictive of embryo morphology or pregnancy outcome in the recipient population.
19. Younis JS, Jadaon J, Izhaki I, et al. A simple multivariate score could predict ovarian reserve, as well as pregnancy rate, in infertile women. Fertil Steril 2010;94:655-661. This prospective cohort study presents a multivariate model, including chronological age, endocrine and sonographic parameters, to have a distinctive prediction of ovarian reserve and pregnancy outcome in ART.
20. Bersinger NA, Wunder D, Birkhauser MH, Guibourdenche J. Measurement of anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid. Clin Chim Acta 2007;384:174-175.
21. Freour T, Mirallie S, Bach-Ngohou K, et al. Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 2007;375:162-164.
22. la Marca A, Sighinolfi G, Radi D, et al. Antimullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-130.
23. Streuli I, Fraisse T, Chapron C, et al. Clinical uses of anti-Mullerian hormone assays: pitfalls and promises. Fertil Steril 2009;91:226-230.
24. Hendriks DJ, Mol BW, Bancsi LF, et al. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 2005;83:291-301.
25. Broer SL, Mol B W J, Hendriks D, Broekmans F J M. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009;91:705-714.
26. Ferraretti AP, La Marca A, Fauser B C J M, et al. On behalf of the ESHRE working group on poor ovarian response definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616-1624. This very recent publication presents for the first time to standardize the definition of POR by the scientific community.
27. Lee TH, Liu CH, Huang CC, et al. Serum antimullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008;23:160-167.
28. Nelson SM, Yates RW, Lyall H, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-875.
29. Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008;23:1359-1365.
30. Nardo LG, Gelbaya TA, Wilkinson H, et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2009;92:1586-1593.
31. Ocal P, Sahmay S, Cetin M, et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011;28:1197-1203. This very recent publication presents that measurement of basal serum AMH and AFC can be used to determine the women with high risk for OHSS.
32. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-697.
33. Fleming R, Deshpande N, Traynor I, Yates RW. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 2006;21:1436-1441.
34. La Marca A, Orvieto R, Giulini S, et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970-972.
35. Loh JS, Maheshwari A. Anti-Müllerian hormone: is it a crystal ball for predicting ovarian ageing? Hum Reprod 2011;26:2925-2932. This study evaluated the evidence basis for using AMH for various indications to decide how justified it is to promote AMH as a crystal ball, until more evidence is available.
36. Li l, Chen X, Mo Y, et al. Elevated serum antimullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr 2010;122:519-524.
37. Coccia ME, Rizzello F. Ovarian reserve. Ann N Y Acad Sci 2008;1127:27-30.
38. Gleicher N, Weghofer A, Barad DH. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril 2010;94:2824-2827.
39. Tehrani FR, Shakeri N, Solaymani-Dodaran M, Azizi F. Predicting age at menopause from serum antimüllerian hormone concentration. Menopause 2011;18:766-770. This study presents that serum AMH concentrations can reasonably forecast the age at menopause for individual women.
40. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010;376:911-921.
41. Broer SL, Eijkemans M J C, Scheffer GJ, et al. Anti-Müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011;96:2532-2539. This very recent publication presents that AMH is highly predictive for timing of menopause. Using age and AMH, the age range in which menopause will subsequently occur can be individually calculated.
42. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465-493.
43. Knauff EA, Eijkemans MJ, Lambalk CB, et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 2009;94:786-792.
44. Amer SA, Li TC, Ledger WL. The value of measuring anti-Mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod 2009;24:2760-2766.
45. Kitajima M, Khan KN, Hiraki K, et al. Changes in serum anti-Müllerian hormone levels may predict damage to residual normal ovarian tissue after laparoscopic surgery for women with ovarian endometrioma. Fertil Steril 2011;95:2589-2591. This study presents that serum AMH levels shows significant decline with consequent depletion of follicles in tissue specimens after surgery for women with ovarian endometrioma.
46. Nelson SM, Yates RW, Fleming R. Serum anti-MüUerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007;22:2414-2421.
47. Lee TH, Liu CH, Huang CC, et al. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol 2009;7:100.
48. La Marca A, Nelson SM, Sighinolfi G, et al. Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 2011;22:341-349. This very recent publication reported that AMH can also predict the outcome of pregnancy.
49. Li H W R, Yeung W S B, Lau E Y L, et al. Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination. Fertil Steril 2010;94:2177-2181. This study presents that serum AMH concentration was significantly higher in women with a live birth from the first cycle or after three cycles of stimulated intrauterine insemination treatment compared with those failing treatment.
50. Streuli I, Fraisse T, Pillet C, et al. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395-400.
51. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007;134:196-201.
52. La Marca A, Giulini S, Orvieto R, et al. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 2005;20:1569-1572.
53. Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology 2002;13:184-190.
54. Fedorcsak P, Dale PO, Storeng R, et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod 2004;19:2523-2528.
55. Lin YH, Chiu WC, Wu CH, et al. Antimüllerian hormone and polycystic ovary syndrome. Fertil Steril 2011;96:230-235. This very recent publication presents that elevated serum AMH levels increase the risk of PCOS but do not affect the risk of insulin resistance or metabolic syndrome.
56. Park HT, Cho GJ, Ahn KH, et al. Association of insulin resistance with antimullerian hormone levels in women without polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2010;72:26-31.
57. Thomson RL, Buckley JD, Moran LJ, et al. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009;24:1976-1981.
58. Moran LJ, Harrison CL, Hutchison SK, et al. Exercise decreases antimüllerian hormone in anovulatory overweight women with polycystic ovary syndrome-a pilot study. Horm Metab Res 2011;43:977-979. This very recent publication presents that exercise is associated with improvements in ovarian hormones in women with abnormal ovarian function. This suggests that mechanisms associated with ovarian dysfunction can be improved by exercise in PCOS.
59. Halawaty S, ElKattan E, Azab H, et al. Effect of obesity on parameters of ovarian reserve in premenopausal women. J Obstet Gynaecol Can 2010;32:687-690.
60. Sahmay S, Guralp O, Senturk LM, et al. Serum antimüllerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. Reprod Med Biol 2011;10:113-120. This very recent publication shows that body mass index does not seem to have an effect on serum AMH levels in reproductive age women both with and without PCOS.
61. Su HI, Sammel MD, Freeman EW, et al. Body size affects measures of ovarian reserve in late reproductive age women. Menopause 2008;15:857-861.